Online ISSN: 2515-8260

Keywords : 2


Antioxidant Activity Of Some Triazoles Synthesized By Click Chemistry

Jalal Hasan Mohammed; Saadon Abdulla Aowda

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 8, Pages 688-704

In this research, eight new compounds were created from the interaction of a number of aromatic and aliphatic compounds with propargyl bromide to prepare the alkynes after that; alkynes is reacted with the organic azide to form eight new compounds of 1,2,3-triazole by click reaction Using copper as a catalyst After that an antioxidant was done For prepared triazole , DPPH radical scavenging activity and It was the best result values 76.54+-1.9 for compound 9 Compared to the standard model ascorbic acid values 86.03+-4.02 at 200 mg/ml concentration

A Convenient Synthesis and Reactions ofsome Substituted 1,2,4-Triazine, and Their Derivatives with Carbazole, Sulfonamide and Trityl Chloride Moiety of Biological Interest

Aarfah Majid; Mohammad Ashid; Nasir Hussain; AjitJoshi .

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 8, Pages 994-1002

A series of 1,2,4-triazine derivatives [1-9] were synthesized by various analogous methods. In this investigation 5,6-diphenyl-1,2,4-triazine-3-thiol compound [1] was prepared by cyclization of benzil with thiosemicarbazide. Further 5-(prop-2-en-1-yl)-5H-[1,2,4] triazino [5,6-b]indole-3-thiol compound [3] was prepared by treating 1-(prop-2-en-1-yl)-1h-indole-2,3-dione compound [2] with thiosemicarbazide. Further a variety of compounds were prepared by hydrogen replacement of compound [1] and compound [3] by differently active halogen containing scaffolds. Compound [1] was reacted with 9-(2-bromoethyl)-9H-carbazole to produce 9-(2-(5,6-diphenyl-1,2,4-triazin-3-yl)thio)ethyl)9-H-carbazole compound [4].After that, the compound [1] was allowed to react with 2-chloro-N-(4-methylbenzene-1-sulfonyl)-N-(pyridine-2-yl) acetamide to synthesize 2-((5,6-diphenyl-1,2,4-triazin-3-yl)-N-(Pyridin-2-yl)-N-tosylacetamide compound [5].In addition to this ,5,6-diphenyl-3-(tritylthio)-1,2,4-triazine compound [6] was also prepared by condensation reaction between trityl chloride and compound [1]. Further, Compound [3] was reacted with 9-(2-bromoethyl)-9H-carbazole to produce 3-((2-(9H-Carbazol-9-yl)ethylthio)-5-allyl-5H-[1,2,4]triazino[5,6-b]triazino[5,6-b]indole compound [7].After that, the compound [3] was allowed to react with 2-chloro-N-(4-methylbenzene-1-sulfonyl)-N-(pyridine-2-yl) acetamide to synthesize 2-((5-allyl-5H-[1,2,4]triazino[5,6-b]infol-3-yl)thio)-N-(pyridine-2-yl)-N-tosylacetamide compound [8].In addition to this ,5-allyl-3-(tritylthio)-5H-[1,2,4]triazino compound [9] was also prepared by condensation reaction between trityl chloride and compound [3]. All the synthesized compounds were confirmed by spectral data (Table 1) and analytical data (Table 2).

A Comparative Study Of A New Combined 4% Hydrophobic Ointment And Psilo-Balsam In Experimental Skin Allergy Of Guinea Pigs

Khayrulla M. Khatamov; Akram A. Suyarov; Tamara U. Aripova; Malika Sh. Foziljonova; Boburjon B. Mutalov

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 3, Pages 3391-3402

Comparative study of a new combined 4% hydrophobic ointment and psilo-balsam in experimental skin allergy of Guinea pigs.
Experimental allergic dermatitis was caused by method of P. M. Zalkan and E. Ievleva using 2,4-dinitrochlorobenzole on Guinea pigs using a 4% combined ointment of a thick extract of Bidens tripartitae and root of licorice and a comparison with drug psilobalzam. It was found that a combined 4% hydrophobic ointment, a thick extract of Bidens tripartitae and a dry extract of licorice root is more effective in the treatment of contact allergic dermatitis than the antihistamine drug psilo-balsam.

Synthesis of a series of new 6-nitrobenzofuran-2-carbohydrazide derivatives with cytotoxic and antioxidant activity

Muhammad Taha; Sadia Sultan; Mohamad Azlan; Syed Adnan Ali Shah; Waqas Jamil; Swee Keong Yeap; Syahrul Imranb; Muhammad Nadeem Akhtar; Seema Zareenf; Nor Hadiani Ismailb; Muhammad Alih

European Journal of Molecular & Clinical Medicine, 2017, Volume 4, Issue 1, Pages 23-30

6-nitrobenzofuran-2-carbohydrazide Schiff base derivatives have been synthesized and their structure has been confirmed via H1NMR, Mass spectrometry and elemental (CHN/S) analysis. These synthesized analogs showed significant cytotoxic and antioxidant activity. Doxorubicin (IC50 = 0.94 ± 0.20 μM) and n-propyl gallate (IC50 = 30.30 ± 0.40 μM) were used as standard in cytotoxic and antioxidant activities, respectively. Compound 1 (IC50 = 3.30 ± 0.90 μM), 2 (IC50 = 2.70 ± 0.25 μM), 3 (IC50 = 2.70 ± 0.25 μM), 10 (IC50 = 2.70 ± 1.10 μM), 11 (IC50 = 1.00 ± 1.20 μM), and 17 (IC50 = 3.75 ± 0.90 μM) showed excellent while 21 (IC50 = 7.50 ± 0.60 μM) and 28 (IC50 = 7.50 ± 0.66 μM) showed moderate anti cancer activity. Furthermore, compound 10 (IC50 = 17.50 ± 0.85 μM), 11 (IC50 = 24.20 ± 0.55 μM), 12 (IC50 = 21.10 ± 1.58 μM), 13 (IC50 = 14.60 ± 0.32 μM), 14 (IC50 = 29.20 ± 0.75 μM) and 15 (IC50 = 9.26 ± 0.15 μM) showed better antioxidant activity than the standard n-propyl gallate. This study will be useful to develop potential lead molecules with cytotoxic and antioxidant potential.

Emerging Pathways in Treating Human epidermal growth factor receptor-2-negative breast Cancer

Sotirios Stergiopoulos

European Journal of Molecular & Clinical Medicine, 2015, Volume 2, Issue 2, Pages 27-38

Breast cancer remains the leading cause of new cancer cases in women and is responsible for the most cancer-related deaths in women worldwide. The goals of breast cancer treatment are to maintain or improve quality of life, prolong survival, and increase disease-free progression. The majority of breast cancer cases are estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER-2)-negative, and current treatment guidelines recommend multiple lines of endocrine therapy followed by chemotherapy in patients with locally recurrent or metastatic disease. Resistance to current therapies adds to the need for new therapeutic options. Translational research and preclinical data have provided insight into the identification of emerging signaling pathways for novel drug targets, and the development of a growing number of biologic targeted agents is currently underway to identify novel treatments. An alternative approach to improve patient benefit is to boost the efficacy and safety of existing agents by modifying their delivery or pharmacokinetics (ie, adding albumin to paclitaxel) as well as identifying new combination therapies. One combination therapy of interest is the addition of the 130 nm albumin-bound formulation of paclitaxel (nab-paclitaxel) to currently approved therapies or targeted agents in development. This review focuses on a number of key agents that are being investigated for the treatment of HER-2-negative breast cancer and the utilization of these agents as combination therapy to achieve prolonged disease control. Focal points • Bedside ○ New therapeutic options are necessary for breast cancer patients with HER-2-negative and either hormone receptor positive or negative disease who develop resistance to current therapies. Recent insights into molecular pathways may soon expand the treatment options for all patients with HER-2-negative breast cancer. • Bench ○ Several rationally designed combinations of biologic targeted agents and next generation chemotherapeutic agents are currently under investigation to prolong disease control and overcome treatment resistance in patients with HER-2-negative breast cancer.